Ligand initiated with a Buy at BofA
BofA initiated coverage of Ligand (LGND) with a Buy rating and $244 price target Citing a portfolio of more than 100 high-value commercial and development assets, increasing needs for flexible, non-dilutive capital in the industry and a lean cost structure, the analyst contends that the biopharma royalty firm can continue to deliver on its “aggressive earnings targets.”
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
See Insiders’ Hot Stocks on TipRanks >>
Read More on LGND:
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Rare Earths Americas doubles mineralized zone at Homer project in Brazil
Wall Street Trading Booms on Crypto Exchanges. Which Tokens Benefit?
CEREBRAS SYSTEMS INC <CBRS.O>: MIZUHO CUTS TARGET PRICE TO $240.00 FROM $300.00
Allarity Therapeutics Sees FY Loss/Shr 73c-Loss 76c >ALLR
Crypto prices
More
